A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

Sponsor
GlaxoSmithKline
Study ID
NCT07224672
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Amyloidosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Belantamab mafodotin — DRUG
    Belantamab mafodotin will be administered
  • Cyclophosphamide — DRUG
    Cyclophosphamide will be administered
  • Bortezomib — DRUG
    Bortezomib will be administered
  • Dexamethasone — DRUG
    Dexamethasone will be administered

Study Details

The study aims to evaluate the efficacy and safety of belantamab mafodotin in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed (ND) AL amyloidosis .

Key Dates

Start date
Mar 20, 2026
Status verified
Mar 2026
Primary completion
Dec 13, 2032
Completion
Dec 13, 2032

Study Design

Enrollment
60 participants (estimated)
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Dose optimization phase: Belantamab mafodotin dose level 1 + CyBorD
    Adult participants with newly diagnosed amyloid light chain (AL) amyloidosis will receive Belantamab mafodotin dose level 1 in combination with CyBorD in dose optimization phase.
  • Experimental: Dose optimization phase: Belantamab mafodotin dose level 2+ CyBorD
    Adult participants with newly diagnosed AL amyloidosis will receive Belantamab mafodotin dose level 2 in combination with CyBorD in dose optimization phase.
  • Experimental: Dose expansion phase: Belantamab mafodotin + CyBorD
    Adult participants with newly diagnosed AL amyloidosis will receive belantamab mafodotin at selected dose level from dose optimization phase in combination with CyBorD in dose expansion phase.

Primary Outcome Measure

Overall complete hematologic response (CHR) rate [ Time Frame: Up to approximately 24 months ]

Central Contacts

Related Studies